Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc

Grade Last Price % Change Price Change
A 23.24 -1.15% -0.27
AUPH closed down 1.15 percent on Friday, September 24, 2021, on 61 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical AUPH trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish -1.15%
Boomer Buy Setup Bullish Swing Setup -1.15%
NR7 Range Contraction -1.15%
Upper Bollinger Band Walk Strength -1.15%
Older End-of-Day Signals for AUPH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Outside Day 1 day ago
Down 3% 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Clinical Development Drugs Autoimmune Diseases Autoimmune Disease Peptides Lupus Nephrology Immunosuppressants Lupus Nephritis Nephritis

Is AUPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.18
52 Week Low 9.721
Average Volume 4,406,097
200-Day Moving Average 14.19
50-Day Moving Average 16.05
20-Day Moving Average 19.86
10-Day Moving Average 21.73
Average True Range 1.50
ADX 40.19
+DI 31.15
-DI 10.71
Chandelier Exit (Long, 3 ATRs) 19.69
Chandelier Exit (Short, 3 ATRs) 19.62
Upper Bollinger Bands 24.35
Lower Bollinger Band 15.38
Percent B (%b) 0.88
BandWidth 45.15
MACD Line 2.05
MACD Signal Line 1.81
MACD Histogram 0.2389
Fundamentals Value
Market Cap 2.93 Billion
Num Shares 126 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -33.34
Price-to-Sales 13945.98
Price-to-Book 4.65
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.06
Resistance 3 (R3) 25.11 24.55 24.75
Resistance 2 (R2) 24.55 24.09 24.53 24.65
Resistance 1 (R1) 23.90 23.81 23.62 23.85 24.55
Pivot Point 23.34 23.34 23.21 23.32 23.34
Support 1 (S1) 22.69 22.88 22.41 22.64 21.93
Support 2 (S2) 22.13 22.60 22.11 21.83
Support 3 (S3) 21.48 22.13 21.73
Support 4 (S4) 21.43